Strongbridge biopharma plc (SBBP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-12,698

-8,980

-13,790

-8,247

-18,434

84,056

-20,559

-2,923

-28,723

-18,748

-35,060

-30,190

-29,485

-16,000

-7,618

-12,896

-12,205

-10,450

-9,666

-17,143

-6,374

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability

-580

-1,307

-3,202

-8,697

1,820

111

-7,131

-19,017

9,700

2,024

-1,953

15,219

14,928

-

-

-

-

-

-

-

-

Stock-based compensation

1,751

1,527

2,175

2,572

2,323

2,018

2,116

1,985

1,688

1,303

1,331

1,364

1,169

1,085

1,103

1,090

1,328

618

503

2,782

37

Amortization of intangible asset

1,256

1,256

1,255

1,255

1,256

1,670

1,876

1,872

1,769

1,255

1,256

1,255

1,256

-

-

-

-

-

-

-

-

Accretion of discounts on marketable securities

-48

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and related guarantee fees paid in kind

-

-

-

-

-

-

1,077

1,047

766

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discounts and debt issuance costs

-

-

-

-

-

375

412

383

314

111

89

142

140

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-21,049

0

0

-500

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax expense

-

-

-

-

-

-

-

-

-

1,154

-795

0

1,599

-

-

-

-

-

-

-

-

Deferred income tax expense (benefit)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-871

-55

-144

-129

-122

-55

Depreciation

21

21

20

18

18

18

18

7

3

2

3

2

3

2

3

2

3

3

2

4

2

Impairment/loss on investment in Antisense Therapeutics

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

550

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

401

-1,073

-2,981

2,427

2,290

-916

166

360

432

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-101

-406

-819

-1,042

649

-2,313

5,075

-475

1,150

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-79

-922

-375

-272

-1,510

1,894

-736

1,303

567

-479

-176

901

198

-945

2

103

-8

9

-1,352

2,520

-12

Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

359

-1,940

2,124

-

-

-

1,520

Other assets

-266

-172

-196

-44

1,210

0

-13

-43

-325

299

86

150

1

1,019

-106

-1,281

456

-

-

-

1

Accounts payable

1,954

1,376

492

-254

539

-2,043

816

243

921

-175

222

-680

791

79

-954

661

-1,488

-1,706

-3,622

6,732

333

Accrued and other liabilities

-6,941

2,062

2,163

-3,681

-3,191

-7,579

6,551

3,019

-3,133

1,633

977

-76

509

-

-

-

-

-

-

-

-

Net cash used in operating activities

-15,240

-1,857

-6,516

-18,103

-18,308

-32,712

-19,316

-14,529

-18,019

-10,886

-9,127

-16,034

-9,289

-6,972

-7,003

-8,444

-9,295

-9,858

-11,837

-11,117

-4,548

Cash flows from investing activities:
Payment for acquisitions

-

-

-

-

-

0

0

0

24,655

0

0

0

7,500

-

-

-

-

-

-

-

-

Purchases of property and equipment

-

32

9

18

15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of marketable securities

14,830

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

21

4

Net cash provided by (used in) investing activities

14,830

-20,719

-9

-18

-15

159,295

0

-310

-24,655

0

0

0

-7,500

-

-

-

-

-1,101

0

-3,189

-4

Cash flows from financing activities:
Proceeds from long-term debt, net

-

-

-

-

-

0

0

0

44,930

-

-

-

-

-

-

-

-

-

-

-

-

Payment for loss on extinguishment of debt

-

-

-

-

-

9,490

0

0

500

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of ordinary shares, net

-

-

-

-

-

0

0

0

33,508

-

-

-

-

-

-

-

-

-

-367

32,544

25,754

Proceeds from exercise of stock options

-

0

-1

14

166

17

20

0

59

-

-

-

-

-

-

-

-

-

-

-

-

Payments related to tax withholding for net-share settled equity awards

68

0

33

32

27

32

0

13

428

-

-

-

-

-

-

-

-

-

-

-

-

Payment for amendment of long-term debt

-

-

-

-

-

-

-

-

-

-

-

0

150

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-68

0

-34

-18

139

-71,476

1,185

7,948

77,569

24,030

19,629

0

-150

-

-

-

-

19,061

45

32,544

25,754

Net decrease in cash and cash equivalents

-478

-22,576

-6,559

-18,139

-18,184

55,107

-18,131

-6,891

34,895

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-21

589

337

234

-919

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-16,939

-

-8,415

-8,423

-9,316

8,691

-11,455

18,472

20,283

Supplemental disclosures of cash flow information: Cash paid during the year for:
Interest

-

-

-

-

-

5,722

1,899

1,859

1,642

-

-

467

295

-

-

-

-

-

-

-

-

Income taxes other, net of refunds

-

-

-

-

-

-

-

-

-

-

-

0

255

-

-

-

-

-

-

-

-

Supplemental non-cash financing activities:
Changes in unrealized gain on marketable securities

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-